Vice versa, disruption of AnxA2/p11 interaction with small molecule inhibitors or AnxA2 antibodies reduced acute lymphoblastic leukemia proliferation and sensitized tumour cells to chemotherapy [173]. Here, S100A10 is linked to neoplasm.